ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
This paper utilized the Delphi method to establish interdisciplinary consensus for the initial investigations, diagnostic imaging, referral pathway and interhospital transfer for patients with acute aortic syndrome. The authors represent the coming together of experts from the multidisciplinary team, as well as members of the public, including patient representatives. This comes following the global patient-led work of THINK AORTA.
The incidence, predictors, and prognostic impact of rehospitalization following transcatheter aortic valve implantation (TAVI) has not been widely investigated and reported. This information is especially missing based on real-world practice data. Hence, the authors retrospectively analyzed a total of 1,397 patients who underwent TAVI between 2016 and 2020 in East Denmark. The medical records of all patients were reviewed to validate rehospitalizations up to one year after discharge from the index TAVI. A total of 615 patients (44 percent) had an unplanned rehospitalization within the first year after TAVI. The incidence of unplanned rehospitalization rate was three times higher in the early post-TAVI period (i.e., within 30 days) compared with the late post-TAVI period (i.e., 30 days to 1 year; 2.5 vs. 0.8 per patient-year, respectively; P < 0.001). Early rehospitalization was most frequently procedure related, whereas late rehospitalization was mostly related to baseline comorbidities. Early and late heart failure related rehospitalization was associated with a considerably higher one and five-year mortality risk (hazard ratio (HR) of 4.3 and 3.2 for 1-year mortality and HR of 3.2 and 2.9 for 5-year mortality, respectively; P < 0.001). Given the elevated frequency of rehospitalization following TAVI and the poor long-term survival associated with heart failure related rehospitalization, the authors conclude that TAVI trials should include rehospitalization as a major study endpoint.
In this LACES “Experts’ Insights” interview, Dr. Michael Borger, co-chair of the recently published 2023 ESC/EACTS Endocarditis Guidelines, briefly summarizes the most important take-home messages and changes of the guidelines.
This article looks at the application of prognostic models within cardiothoracic surgery, and medicine in general, using a televised UK dance competition where professional dancers are paired with celebrities as an illustration. The authors use available data from previous series to make predictions about the outcome of the competition and highlight the pitfalls of misapplication of prognostic models, particularly when extrapolating conclusions from demographic data alone.
The ISCHEMIA trial has caused heated discussion in the cardiovascular field, with its results being used to downgrade coronary artery bypass grafting (CABG) recommendations in recent guidelines. The authors of this paper performed a detailed re-analysis of the ISCHEMIA trial and critically examined its findings. Several factors are judged likely to have diluted the potential survival advantage associated with CABG. The authors concluded that the results of ISCHEMIA have been misinterpreted, that they are aligned with previous evidence and should not be used to downgrade recommendations for CABG.
This article is a registry review form an international voluntary registry. The retrospective historical data can be juxtaposed favorably with the recently published article on acute dissection in Denmark from a compulsory national registry. The main strength of the paper is the succinct discussion.
Non-inferiority study designs are frequently used in randomized controlled trials (RCT) comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). However, the long-term outcomes of TAVR are unknown, and the concept of non-inferiority is challenging to define and assess. This systematic review and meta-analysis published in Interdisciplinary Cardiovascular and Thoracic Surgery (ICVTS) compares TAVR and SAVR, specifically emphasizing the non-inferiority margin for five-year all-cause mortality. To this end, the authors performed a systematic search in three electronic databases. A total of eight RCTs (n = 8,698 patients) comparing TAVR and SAVR were included. Bayesian methods were implemented to evaluate the posterior probability of non-inferiority at different trial non-inferiority margins. The primary study outcomes were five-year actuarial all-cause mortality and the probability of non-inferiority at various transformed trial non-inferiority margins. Kaplan-Meier-derived five-year survival was 61.6 percent (95 percent CI 59.8–63.5 percent) for TAVR and 63.7 percent (95 percent CI 61.9–65.6 percent) for SAVR. The posterior median relative risk for all-cause mortality of TAVR was 1.14 compared to SAVR. The posterior probability of a mortality difference in favor of SAVR was 99.9 percent. The authors concluded that the non-inferiority of TAVR compared to SAVR is unlikely after five years in terms of all-cause mortality.
Minimally invasive mitral valve surgery (MIMVS) is feasible and safe, but its uptake has lagged worldwide. The authors conducted a detailed survey of 75 surgeons, of whom 32 (42 percent) completed the survey. All who completed the survey performed more than 25 MIMVS cases annually. 62 percent used a fully endoscopic approach, whereas 52 percent had used endoscopically assisted strategies. Smaller proportions had used direct visualization (17 percent) or a robot (20 percent). There was wide variability in views on the necessary training and approach to MIMVS, suggesting that consensus guidelines should be established.
Degenerative aortic valve stenosis is the most frequent valvular heart disease in western countries, and valve replacement is the gold standard for symptomatic severe cases. In addition to the two established procedures (surgical aortic valve replacement [SAVR] and transcatheter aortic valve implantation [TAVI]), the last decade showed the rising of a third way, which is based on the concept of the surgical replacement but takes some advantages of the TAVI prosthesis's design, such as the faster and simpler anchoring mechanism. This category includes the interventions performed with the sutureless and the rapid deployment prostheses. Sutureless and rapid-deployment (SURD-AVR) has been applied to high- and intermediate-risk populations with good clinical results. However, concerns were raised because of the incidence of postprocedural permanent pacemaker implantation (PPI), which was higher than in conventional SAVR and similar to that observed following TAVI. Possible factors associated with this complication have been assessed only in single-center studies with small sample populations. Moreover, recent analyses reported a reduction of this complication over time, suggesting the possible role of a time bias or learning curve effect. For these reasons, the authors aimed to investigate the need for PPI following SURD-AVR in a large cohort using a progress report approach.
In this study, the authors performed a propensity matched analysis of hospital costs for robotic-assisted CABG vs. conventional CABG. 1,173 patients were included in the analysis from 2018 until 2021. Decision regarding intervention modality was decided by the treating surgeon. Following propensity matching, the sample consisted of 267 patients per group. Total costs considered those both directly and indirectly related to the surgery including operating room time, hospital stay, expendables, medical records, and administrations.